DEVELOPMENT AND VALIDATION OF THE HPTLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF RAMIPRIL AND HYDROCHLOROTHIAZIDE IN SOLID DOSAGE FORM

Ramipril is an angiotensin-converting enzyme inhibitor and is used in treating high blood pressure. Hydrochlorothiazide is a diuretic drug that increases urine output. High-Performance Thin-Layer Chromatography is a sophisticated form of thin-layer chromatography which is a separation technique and is used in various bioavailability studies to study marketed formulations as well as novel therapeutic agents. We aimed to develop and validate a simple, precise, accurate, and rapid HPTLC method for the simultaneous estimation of Ramipril and Hydrochlorothiazide in the combined solid dosage form. Precoated silica gel G₆₀F₂₅₄ was used as the stationary phase. The mobile phase used was a mixture of methanol: toluene: ethyl acetate: glacial acetic acid (1:6:3:0.5 %v/v). Spot detection was carried out at 210 nm. Validation of the method was done in terms of linearity, accuracy, precision, and specificity. A linear calibration curve was obtained between 2000 to 12000 ng/spot for Ramipril and 500 to 3000 ng/spot for Hydrochlorothiazide. The limit of detection and the limit of quantification for the Ramipril was found to be 434.1 and 1315.483 ng/spot, respectively, and for Hydrochlorothiazide 80.6 and 244.31 ng/spot, respectively. The drug content of the marketed formulation was successfully determined by the proposed validate method.